IMBRIUM THERAPEUTICS Trademark

Trademark Overview


On Friday, June 14, 2019, a trademark application was filed for IMBRIUM THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the IMBRIUM THERAPEUTICS trademark a serial number of 88977524. The federal status of this trademark filing is REGISTERED as of Tuesday, June 9, 2020. This trademark is owned by Purdue Pharma L.P.. The IMBRIUM THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of central nervous system disorders
imbrium therapeutics

General Information


Serial Number88977524
Word MarkIMBRIUM THERAPEUTICS
Filing DateFriday, June 14, 2019
Status700 - REGISTERED
Status DateTuesday, June 9, 2020
Registration Number6076745
Registration DateTuesday, June 9, 2020
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, October 15, 2019

Trademark Statements


Description of MarkThe mark consists of a series of seven parallel lines of different sizes, with the first four lines increasing in size to the fourth line and thereby decreasing in size from the fifth to the seventh lines, followed by a single vertical line next to the word "IMBRIUM" in large capital letters over the word "THERAPEUTICS" in small capital letters.
Goods and ServicesPharmaceutical preparations for the treatment of central nervous system disorders
Indication of Colors claimedColor is not claimed as a feature of the mark.
NOT AVAILABLE"THERAPEUTICS"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 27, 2019
Primary Code005
First Use Anywhere DateTuesday, September 24, 2019
First Use In Commerce DateTuesday, September 24, 2019

Trademark Owner History


Party NamePurdue Pharma L.P.
Party Type30 - Original Registrant
Legal Entity Type13 - Limited Partnership
AddressStamford, CT 06901

Party NamePurdue Pharma L.P.
Party Type20 - Owner at Publication
Legal Entity Type13 - Limited Partnership
AddressStamford, CT 06901

Party NamePurdue Pharma L.P.
Party Type10 - Original Applicant
Legal Entity Type13 - Limited Partnership
AddressStamford, CT 06901

Trademark Events


Event DateEvent Description
Tuesday, June 18, 2019NEW APPLICATION ENTERED
Thursday, June 27, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, June 28, 2019NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, September 5, 2019ASSIGNED TO EXAMINER
Friday, September 6, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 25, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 15, 2019PUBLISHED FOR OPPOSITION
Tuesday, October 15, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 10, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, March 23, 2020TEAS REQUEST TO DIVIDE RECEIVED
Monday, March 23, 2020TEAS STATEMENT OF USE RECEIVED
Monday, March 23, 2020DIVISIONAL REQUEST RECEIVED
Monday, March 23, 2020USE AMENDMENT FILED
Wednesday, April 15, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, April 15, 2020ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST
Thursday, April 16, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 16, 2020RESPONSE TO ITU OFFICE ACTION ENTERED
Monday, April 20, 2020DIVISIONAL PROCESSING COMPLETE
Monday, April 20, 2020STATEMENT OF USE PROCESSING COMPLETE
Thursday, May 7, 2020ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, June 9, 2020REGISTERED-PRINCIPAL REGISTER
Monday, June 9, 2025COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, May 8, 2020NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, April 21, 2020NOTICE OF DESIGN SEARCH CODE E-MAILED
Tuesday, April 21, 2020ASSIGNED TO EXAMINER